FindTrial
Sign In

Hypofractional IMRT using simultaneous integrated boost in breast conservation for early-stage breast cancer

Hypofractional IMRT using simultaneous integrated boost in breast conservation for early-stage breast cancer

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-17010838
Enrollment
Unknown
Registered
2017-03-10
Start date
2016-01-26
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

study group 1:hypofractional radiotherapy43.5Gy/15F+ simultaneous integrated boost8.7Gy/15F
study group 2:conventional radiotherapy50Gy/25F+simultaneous integrated boostDT10Gy/5F
control group:conventional radiotherapy50Gy/25F+sequential boostDT10Gy/5F

Sponsors

Zhejiang Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
40 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Women aged between 40 and 75 years old; 2. Histologically confirmed diagnosis of invasive breast carcinoma; 3. Early breast cancer (pathological staging T1-2N0M0); 4. Treated with breast conserving surgery.

Exclusion criteria

Exclusion criteria: 1. Person who does not meet the inclusion criteria; 2. Women who are pregnant; 3. Multifocal or multicentric tumours; 4. history of radiation treatment in chest; 5. History of vascular collagen disease.

Design outcomes

Primary

MeasureTime frame
locoregional control rate;Grade 2 or 3 fibrosis;—

Secondary

MeasureTime frame
Any other late morbidity after adjuvant radiotherapy;overall survival;—

Countries

China

Contacts

Public ContactWang Shengye

Zhejiang Cancer Hospital

joycewang04@163.com+86 0571-88128172

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026